PTC Therapeutics (NASDAQ:PTCT) had its price target dropped by stock analysts at Wedbush from $81.00 to $65.00 in a research note issued on Friday, StockTargetPrices.com reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price objective indicates a potential upside of 84.40% from the stock’s previous close. A number of […]
